Answers are grounded in this paper and cite their sources.
Observational analysis reveals survival benefits and characteristics of fast recovery in STEMI-CS population, indicating further investigation is needed.
The DanGer Shock trial showed a survival benefit of mAFP use in STEMI-CS, yet about one-third of SoC patients experienced rapid haemodynamic recovery. These 'Fast Recovery' patients were characterized by higher LVEF, younger age, and lower lactate, however discrimination between patients with and without rapid recovery was modest. Distinguishing patients who will recover rapidly remains challenging and warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Beske et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: